2.4.3. Prohibited concomitant drugs.
The following concomitant drugs and therapies are prohibited during the study period.Drugs with immunosuppressive properties: tacrolimus excluding the study drug, azathioprine, mizoribine, mycophenolate mofetil, cyclophosphamide, gusperimus, everolimus, ciclosporin, basiliximab, infliximab, etanercept, golimumab, tocilizumab, canakinumab, rituximab, and abatacept.Live vaccines.Bosentan.Potassium-sparing diuretics: spironolactone, potassium canrenoate, and triamterene.Other investigational or unapproved domestic drugs.